RxTrials Institute Drug Pipeline Alert

French drugmaker Ipsen and California’s The Salk Institute for Biological Studies will sign a memorandum of understanding setting the framework for the creation of the Ipsen Life Sciences Program at The Salk Institute.

Ipsen will provide funding for research programs in the field of proliferative diseases with a particular emphasis on novel therapeutic concepts for the treatment of pituitary adenomas, the company said.

Core grants will support research on the contribution of chronic inflammation to malignant diseases such as cancer, loss of cognitive functions, movement disorders and metabolic syndromes.